BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Julina Post-marketing Surveillance for Climacteric Symptoms in Japan

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: E2 transdermal (Julina, BAY86-5435)

First Posted Date: 2011-07-01

Last Posted Date: 2018-04-17

Lead Sponsor: Bayer

Target Recruit Count: 506

Registration Number: NCT01386281

Self Selection Trial of Naproxen Sodium

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Naproxen sodium ER (BAYH6689)
Drug: Advil

First Posted Date: 2011-06-28

Last Posted Date: 2015-10-15

Lead Sponsor: Bayer

Target Recruit Count: 253

Registration Number: NCT01383486

Magnevist Post-marketing Surveillance in Japan

Completed

Conditions: Diagnostic Imaging

Interventions: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)

First Posted Date: 2011-06-20

Last Posted Date: 2011-06-20

Lead Sponsor: Bayer

Target Recruit Count: 2051

Registration Number: NCT01376739

YAZ Post-marketing Surveillance in Japan

Completed

Conditions: Dysmenorrhea

Interventions: Drug: EE20/DRSP(YAZ, BAY86-5300)

First Posted Date: 2011-06-20

Last Posted Date: 2019-03-07

Lead Sponsor: Bayer

Target Recruit Count: 3273

Registration Number: NCT01375998

Safety Trial of Naproxen Sodium/ Diphenhydramine

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)

First Posted Date: 2011-06-03

Last Posted Date: 2015-06-08

Lead Sponsor: Bayer

Target Recruit Count: 326

Registration Number: NCT01365052

Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease

Completed

Conditions: Hypertension

Interventions: Drug: Nifedipine (Adalat CR, BAYA1040)

First Posted Date: 2011-06-01

Last Posted Date: 2015-04-06

Lead Sponsor: Bayer

Target Recruit Count: 1882

Registration Number: NCT01363336

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

Phase 3

Completed

Conditions: Common Cold
Pharyngitis
Tonsillitis

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Drug: Placebo
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Drug: Lidocain

First Posted Date: 2011-05-26

Last Posted Date: 2023-10-18

Lead Sponsor: Bayer

Target Recruit Count: 1088

Registration Number: NCT01361399

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Atopic Dermatitis
Eczema

Interventions: Drug: Vehicle without active
Drug: Mapracorat

First Posted Date: 2011-05-25

Last Posted Date: 2015-01-21

Lead Sponsor: Bayer

Target Recruit Count: 197

Registration Number: NCT01359787

High Dose BAYA1040 CR: a Long Term Extension Study

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Nifedipine (Adalat, BAYA1040)

First Posted Date: 2011-05-18

Last Posted Date: 2014-01-29

Lead Sponsor: Bayer

Target Recruit Count: 120

Registration Number: NCT01355367

Efficacy of Ventavis Used in Real-life Setting.

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Inhaled iloprost (Ventavis, BAYQ6256)

First Posted Date: 2011-05-18

Last Posted Date: 2017-10-17

Lead Sponsor: Bayer

Target Recruit Count: 55

Registration Number: NCT01355380

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy